Drug intelligence / Profile preview

PF-06444753

Development stage: Phase 1
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-06444753 is an anti-IgE vaccine developed by Pfizer. It is being investigated in a Phase 1 clinical trial for the treatment of allergic rhinitis. As a biological intervention, it aims to modulate the immune response by inducing the body to produce antibodies against Immunoglobulin E (IgE), a key mediator in allergic reactions.

Other names: Anti-IgE vaccine

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on PF-06444753.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06444753.

Explore the full profile